Retatrutide: legal

Retatrutide is not an approved medicine anywhere. That is Lilly's own statement in its October 2026 lawsuit against a seller, where Lilly is a party: “no retatrutide medicine has yet been approved by FDA or any other regulatory agency in the world”.[1] This page summarises what regulators have said; it is not legal advice, and it does not cover every country.

United States

The FDA says unapproved retatrutide products “have not been found safe and effective for any condition”, and that “Retatrutide and cagrilintide cannot be used in compounding under federal law”.[2] It reports enforcement on several fronts: “The agency has warned telehealth companies for marketing unapproved drugs such as retatrutide”, and has also warned “active pharmaceutical ingredient distributors for selling retatrutide and other GLP-1 drugs to compounders”.[2] The FDA says it also “has warned companies that have illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide, or mazdutide” under a research-only or not-for-human-consumption label.[2] In one of its complaints Lilly, a party to the case, puts its position bluntly: “Research use only products are, definitionally, not for human use.”[3]

Lilly has sued sellers, beginning in August 2026.[3] Those cases are covered in Lilly v. the retatrutide sellers.

On the approved-drug path, the company states that “Lilly plans to submit a Biologics License Application (BLA) for retatrutide to FDA in Q1 2027”.[4] BioSpace reports a dispute over that route: “the FDA determined that retatrutide is neither a protein nor a biological product”.[5] Until a submission is approved, there is no approved retatrutide medicine.[1]

Federal peptide policy is covered separately in A regulated peptide market.

United Kingdom

The Medicines and Healthcare products Regulatory Agency (MHRA) treats these pens as unlicensed or counterfeit medicines and has seized them in bulk. In October 2025 it reported finding “more than 2,000 unlicensed retatrutide and tirzepatide pens awaiting dispatch to customers”.[6] In October 2026 it reported that “over 12,000 fake retatrutide and tirzepatide pens were seized along with packaging for around 30,000 more products”, and warned that “there is no guarantee of what they contain or whether they have been contaminated with harmful substances”.[7]

Australia

Victoria's health department, in a June 2026 alert on liver injury, states that “retatrutide is an experimental drug not approved for sale as a safe medical product in Australia”.[8]

References

1. Eli Lilly and Company v. American Peptides LLC, No. 5:26-cv-04146 (W.D. La.), Complaint, filed 10/08/26 — US District Court, via CourtListener RECAP
2. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of 10/01/2026), Wayback capture of 19 October 2026 — US Food and Drug Administration
3. Eli Lilly and Company v. Texas Peptides Inc., complaint (ECF 1) — US District Court, W.D. Tex., case 5:26-cv-05146, filed 2026-08-12, via CourtListener RECAP
4. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials (news release, July 23, 2026), Wayback capture of 12 October 2026 — Eli Lilly and Company
5. Lilly, FDA retatrutide biologic dispute comes to a head as submission nears (August 5, 2026) — BioSpace
6. MHRA smashes major illicit weight loss medicine production facility in record seizure (24 October 2025) — Medicines and Healthcare products Regulatory Agency (GOV.UK)
7. Counterfeit weight loss pens worth £2 million seized by MHRA and West Midlands Police (15 October 2026), Wayback capture of 19 October 2026 — Medicines and Healthcare products Regulatory Agency (GOV.UK)
8. Toxicity linked to unapproved peptide product labelled Retatrutide (health alert, 19 June 2026) — Department of Health, Victoria, Australia